A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...

Wegovy is a GLP-1 agonist containing semaglutide ... 6-month study of Rybelsus found an average drop of 1 to 1.3% A1C in adults with a starting A1C of 8.3%. While Rybelsus is not a weight loss ...

Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...

Those considering semaglutide for weight loss treatment may wonder about dosing ... And people can experience uncomfortable side effects in the first month with this lower dose.

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity treatments continue to improve.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a ...